Effect of rosuvastatin and eicosapentaenoic acid on neoatherosclerosis: the LINK-IT Trial
Kuroda K, Otake H, Shinohara M, Kuroda M, Tsuda S, Toba T, Nagano Y, Toh R, Ishida T, Shinke T, Hirata KI
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 19 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- Japan Society for the Promotion of Science
- Subvenciones
- Japan Society for the Promotion of Science (18K08072); Japan Society for the Promotion of Science (17K09579); Japan Society for the Promotion of Science (17K09553)
Según 1 financiador declarado.
Publicación
- Publicado
- 2019-12-01 · EuroIntervention · vol. 15 · número 12 · págs. e1099–e1106
- Editorial
- European Association of Percutaneous Cardiovascular Interventions
- Citado
- 22 citas · más que el 89% de estudios similares · 2.5× el promedio de su campo
- Referencias
- 13 trabajos
- Acceso
- De pago
- Áreas de investigación
- Lipoproteins and Cardiovascular Health · Cancer, Lipids, and Metabolism · Liver Disease Diagnosis and Treatment
- Palabras clave
- Rosuvastatin, Medicine, Eicosapentaenoic acid, Internal medicine, Rosuvastatin Calcium, Gastroenterology, Urology, Fatty acid, Polyunsaturated fatty acid, Biochemistry
- MeSH
- humans, eicosapentaenoic acid, anticholesteremic agents, hydroxymethylglutaryl-coa reductase inhibitors, tomography, optical coherence, treatment outcome, prospective studies, dose-response relationship, drug, atherosclerosis, rosuvastatin calcium
11 autores
- Koji Kuroda🇯🇵Kobe University
- Hiromasa Otake
- Masakazu Shinohara
- Masaru Kuroda
- Shigeyasu Tsuda
- Takayoshi Toba
- Yuichiro Nagano
- Ryuji Toh
- Tatsuro Ishida
- Toshiro Shinke
- Ken–ichi Hirata
Resumen
El texto original del estudio, en el idioma en que se publicó.
Aims
We aimed to assess the effect of 10 mg/day of rosuvastatin plus eicosapentaenoic acid (EPA) versus 2.5 mg/day of rosuvastatin on the extent of neoatherosclerosis using optical coherence tomography (OCT).
Methods and results
We randomly assigned 50 patients with non-obstructive neoatherosclerotic plaques detected on OCT to receive either rosuvastatin 10 mg/day and EPA 1,800 mg/day (intensive therapy group) or rosuvastatin 2.5 mg (standard therapy group). Follow-up OCT was performed one year later to evaluate serial changes in neoatherosclerosis. The serum low-density lipoprotein cholesterol (LDL-C) level decreased significantly from baseline to 12-month follow-up in the intensive therapy group (89 mg/dL to 70 mg/dL; p<0.001), while no change occurred in the standard therapy group. Lipid index change and percent changes in macrophage grade were significantly lower in the intensive therapy group than in the standard therapy group (-53.6 vs 310.1, p=0.001; -37.0% vs 35.3%, p<0.001; respectively). Percent changes in lipid index and macrophage grade were positively correlated with the changes in serum LDL-C and C-reactive protein levels, and negatively correlated with the change in serum EPA/arachidonic acid and 18-hydroxyeicosapentaenoic acid (EPA bioactive metabolite) level.
Conclusions
Compared with rosuvastatin 2.5 mg/day, rosuvastatin 10 mg/day and EPA 1,800 mg/day significantly stabilised non-obstructive neoatherosclerotic plaques.
Clinical trial registration
UMIN ID: UMIN000012576. https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014711.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.